BESUNYEN Reports Interim Results with Net Profit of 15.066 Million Yuan, Up 21.48% Year-on-Year

Deep News

Aug 09

BESUNYEN (00926) has released its interim results for the six months ended June 30, 2026. The company recorded revenue of RMB 305 million (same unit below), representing a year-on-year increase of 17.74%. Net profit reached 15.066 million yuan, reflecting a 21.48% rise compared to the same period last year. Basic earnings per share stood at 0.12 yuan.

The company attributed the revenue growth primarily to the strong performance of its four-tea product line, which saw a substantial 43.8% increase in revenue. However, this growth was partially offset by a decline in sales of other pharmaceutical products and health supplements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1189955888"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1189955888\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1189955888?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-09 10:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189955888","market":"sh","top_or_hot":-1,"title":"BESUNYEN Reports Interim Results with Net Profit of 15.066 Million Yuan, Up 21.48% Year-on-Year","media":"Deep News","content":"<p><b>BESUNYEN</b> (00926) has released its interim results for the six months ended June 30, 2026. The company recorded revenue of RMB 305 million (same unit below), representing a year-on-year increase of 17.74%. Net profit reached 15.066 million yuan, reflecting a 21.48% rise compared to the same period last year. Basic earnings per share stood at 0.12 yuan.<br><br>The company attributed the revenue growth primarily to the strong performance of its four-tea product line, which saw a substantial 43.8% increase in revenue. However, this growth was partially offset by a decline in sales of other pharmaceutical products and health supplements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BESUNYEN Reports Interim Results with Net Profit of 15.066 Million Yuan, Up 21.48% Year-on-Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBESUNYEN Reports Interim Results with Net Profit of 15.066 Million Yuan, Up 21.48% Year-on-Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-08-09 10:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>BESUNYEN</b> (00926) has released its interim results for the six months ended June 30, 2026. The company recorded revenue of RMB 305 million (same unit below), representing a year-on-year increase of 17.74%. Net profit reached 15.066 million yuan, reflecting a 21.48% rise compared to the same period last year. Basic earnings per share stood at 0.12 yuan.<br><br>The company attributed the revenue growth primarily to the strong performance of its four-tea product line, which saw a substantial 43.8% increase in revenue. However, this growth was partially offset by a decline in sales of other pharmaceutical products and health supplements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1237","symbol_name":"包装食品与肉类","start_time":0,"source_url":"","article_id":"1189955888","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189955888","pubTimestamp":1786243241,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"BESUNYEN (00926) has released its interim results for the six months ended June 30, 2026. The company recorded revenue of RMB 305 million (same unit below), representing a year-on-year increase of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1237":"包装食品与肉类","00926":"碧生源"},"translate_title":"碧生源公布中期业绩，净利润1506.6万元，同比增长21.48%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00926":1},"content_text":"BESUNYEN (00926) has released its interim results for the six months ended June 30, 2026. The company recorded revenue of RMB 305 million (same unit below), representing a year-on-year increase of 17.74%. Net profit reached 15.066 million yuan, reflecting a 21.48% rise compared to the same period last year. Basic earnings per share stood at 0.12 yuan.The company attributed the revenue growth primarily to the strong performance of its four-tea product line, which saw a substantial 43.8% increase in revenue. However, this growth was partially offset by a decline in sales of other pharmaceutical products and health supplements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}